Last Updated : May 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Kalydeco | Ivacaftor | Cystic fibrosis, G551D mutation | List with criteria/condition | Complete | ||
| Eliquis | Apixaban | Thromboembolic events prevention, (atrial fibrillation) | List with clinical criteria and/or conditions | Complete | ||
| Oralair | Grass Pollen Allergen Extract | Allergic rhinitis | List with criteria/condition | Complete | ||
| Afinitor | Everolimus | Advanced Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xiaflex | Collagenase clostridium histolyticum | Dupuytren’s contracture | List with criteria/condition | Complete | ||
| Inlyta | Axitinib | Metastatic Renal Cell Carcinoma | Reimburse | Complete | ||
| Dificid | Fidaxomicin | Clostridium difficile infection | Do not list at the submitted price | Complete | ||
| Latuda | Lurasidone | Schizophrenia | Do not list | Complete | ||
| Samsca | Tolvaptan | Hyponatremia, non-hypovolemic | Do not list | Complete | ||
| Jakavi | Ruxolitinib | Myelofibrosis | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 19, 2024